Infliximab Biosimilar Market Drivers Challenges and Expansion Potential in Global Healthcare Sector

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1060

Infliximab is a chimeric monoclonal antibody targeting tumor necrosis factor-alpha (TNF-α), utilized in the treatment of several chronic inflammatory conditions, including ankylosing spondylitis, Crohn's disease, psoriasis, psoriatic arthritis, rheumatoid arthritis, and ulcerative colitis. The biosimilar version of infliximab has demonstrated comparable efficacy and safety to the original biologic, commonly marketed under the brand name Remicade. Infliximab is produced through continuous perfusion of a recombinant cell line. TNF-α is a proinflammatory cytokine that plays a critical role in the pathogenesis of various chronic inflammatory diseases.

Key factors driving the growth of the infliximab biosimilar market include the increasing prevalence of autoimmune diseases-particularly plaque psoriasis and rheumatoid arthritis-the early expiration of patents on branded products, competitive pricing across European markets, and the rapid therapeutic response facilitated by intravenous administration. Additionally, government policies and third-party payer initiatives aimed at reducing healthcare costs have accelerated the adoption of infliximab biosimilars. Other contributors to market expansion include the cost-effectiveness of biosimilars, rising incidence of chronic conditions such as cancer and autoimmune diseases, and an aging global population.

However, market growth is tempered by certain challenges, including limited physician acceptance, a relatively modest price advantage compared to small-molecule generics, and prolonged patent protections in some regions. Furthermore, the global infliximab market faces constraints due to adverse drug reactions such as histoplasmosis, bacterial sepsis, and tuberculosis, which may affect its broader adoption.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-02

Europe dominated the biosimilars market, followed by Asia-Pacific and North America. Several factors are driving growth in these markets, including the upcoming patent expiration of biological drugs and the introduction of new biosimilars, the rise of new businesses and early market entry. North America is anticipated to be the major contributor to the Infliximab Biosimilar market over the forecast years. The global market is driven by the rise in the prevalence of autoimmune and genetic conditions such as plaque psoriasis and rheumatoid arthritis. The market is developing as a result of rising geriatric populations that lack access to suitable diagnostic and therapeutic options, improved health care infrastructure, and untapped markets. The worldwide infliximab biosimilars market in this region is also predicted to be driven by an increase in government funding for the production of biosimilar medicines as well as increased awareness and adoption of biosimilars.

Major market players operating in the Infliximab Biosimilar market include
Napp Pharmaceuticals Group Ltd, Alvogen, Merck &Co. Inc., Celltrion Inc., Janssen Biotech Inc., Pfizer Inc. (AC. Hospira), and Nippon Kayaku.

Recent collaborations and agreements in the market:
• In April 2021, Novartis AG (Sandoz) struck a deal with Bio-Thera Solutions (China) to commercialise BAT1706 (Bio-Thera Solutions' proposed bevacizumab biosimilar) in the United States, Canada, Europe, and other international markets.
• In November 2019, Biogen Inc, a multinational biotechnology company headquartered in Cambridge, Massachusetts, purchased Samsung Bioepis Co., Ltd. in order to obtain exclusive rights to market two new ophthalmology biosimilars, SB11 referencing Lucentis 1 and SB15 referencing Eylea 2, in major markets around the world, including the United States, Canada, Europe, Japan, and Australia. The deal allows Biogen to prolong the commercialization time for Samsung Bioepis' three anti-TNF biosimilars, BENEPALI (etanercept), FLIXABI (infliximab), and IMRALDI, in Europe (adalimumab). Samsung Bioepis is a biopharmaceutical company. It makes biosimilar medications and other related products.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1060

Market Segments
Global Infliximab Biosimilar Market, by Application, 2022-2030 (Value US$ Mn)
• Crohn's Disease
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis
• Ankylosing Spondylitis
• Plaque Psoriasis and others
Global Infliximab Biosimilar Market, by End User, 2022-2030 (Value US$ Mn)
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy
• Other Direct Distribution Channels
Global Infliximab Biosimilar Market, by Mode, 2022-2030 (Value US$ Mn)
• Prescription-Based Testing Products
• Over-the-Counter (OTC) Testing Product
Global Infliximab Biosimilar Market, by End-Users, 2022-2030 (Value US$ Mn)
• Home Care/Self Testing
• Physician offices & Outpatient/Ambulatory Care Settings
• Hospitals
• Research Laboratories
Global Infliximab Biosimilar Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa
North America Infliximab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada
Europe Infliximab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe
Asia Pacific Infliximab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand
Latin America Infliximab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa Infliximab Biosimilar Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global Infliximab Biosimilar market
 To receive an industry overview and future trends of the Infliximab Biosimilar market
 To analyze the Infliximab Biosimilar market drivers and challenges
 To get information on the Infliximab Biosimilar market value (US$Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the Infliximab Biosimilar market industry

Read Overview Report- https://www.insightaceanalytic.com/report/global-infliximab-biosimilar-market-/1060

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.